Literature DB >> 11738928

Early treatment cost in epilepsy and how it varies with seizure type and frequency.

C E Begley1, D R Lairson, T F Reynolds, S Coan.   

Abstract

The purpose of this paper is to describe the temporal pattern of healthcare cost in two population-based samples of new cases of epilepsy from two different regions of the US, and show how it varies with seizure type and frequency. Epilepsy-related healthcare cost from onset through 4 years of follow-up was determined for two population-based incident samples from Houston, TX and Rochester, MN. Cases were identified over the period 1987-1991 and followed through 1994. Annual use and cost was calculated for the first through fourth year of treatment for each person in the combined samples to examine the temporal pattern of early treatment cost. A multivariate model was estimated to examine how seizure type and seizure frequency affect early treatment cost while controlling for location, age, gender, and ethnicity. Our estimates indicate high initial healthcare cost at onset for most patients followed by lower cost in subsequent years. The mean annual epilepsy-related healthcare cost per patient was $3157 for the first year, $702 for the second year, $471 for year three, and $411 for year four. Cost was significantly higher for groups whose seizures continued and were relatively frequent, but was not significantly different for groups with partial seizures as compared with primary generalized seizures. There was a 2.2-fold difference in 4-year cost between patients with a single seizure at onset and those having recurrent seizures at the rate of more than one per month, controlling for seizure type, age, gender, and ethnicity.

Entities:  

Mesh:

Year:  2001        PMID: 11738928     DOI: 10.1016/s0920-1211(01)00310-2

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  9 in total

1.  The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.

Authors:  Ben A van Hout; Dennis D Gagnon; Pauline McNulty; Anthony O'Hagan
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Economic burden of epilepsy among the privately insured in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Yohanne Kidolezi; Ying Qiu; David Mallett; Sue Caleo
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.

Authors:  Robert Torregrosa; Xiao-Fang Yang; Erik T Dustrude; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

4.  Health care charges for youth with newly diagnosed epilepsy.

Authors:  Jamie L Ryan; Meghan E McGrady; Shanna M Guilfoyle; Katherine Junger; Alex D Arnett; Avani C Modi
Journal:  Neurology       Date:  2015-07-10       Impact factor: 9.910

5.  Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; Ki Duk Park; Pierre Morieux; Robert Swendiman; Erica DeMarco; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

6.  Quality of Life Changes and Health Care Charges Among Youth With Epilepsy.

Authors:  Jamie L Ryan; Meghan E McGrady; Shanna M Guilfoyle; Katherine Follansbee-Junger; James L Peugh; Kristin A Loiselle; Alex D Arnett; Avani C Modi
Journal:  J Pediatr Psychol       Date:  2015-10-26

Review 7.  Childhood febrile seizures: overview and implications.

Authors:  Tonia Jones; Steven J Jacobsen
Journal:  Int J Med Sci       Date:  2007-04-07       Impact factor: 3.738

Review 8.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

Review 9.  Bridging the Gap between Evidence and Practice for Adults with Medically Refractory Temporal Lobe Epilepsy: Is a Change in Funding Policy Needed to Stimulate a Shift in Practice?

Authors:  Alireza Mansouri; Abdulrahman Aldakkan; Magda J Kosicka; Jean-Eric Tarride; Taufik A Valiante
Journal:  Epilepsy Res Treat       Date:  2015-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.